Your browser doesn't support javascript.
loading
Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and persons with underlying illnesses in Belgium.
Blommaert, Adriaan; Bilcke, Joke; Vandendijck, Yannick; Hanquet, Germaine; Hens, Niel; Beutels, Philippe.
Afiliação
  • Blommaert A; Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium; Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BIOSTAT), Hasselt University, Hasselt, Be
  • Bilcke J; Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium.
  • Vandendijck Y; Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BIOSTAT), Hasselt University, Hasselt, Belgium.
  • Hanquet G; Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium.
  • Hens N; Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium; Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BIOSTAT), Hasselt University, Hasselt, Be
  • Beutels P; Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium; School of Public Health and Community Medicine, The University of New South Wales, Sydney, Australia.
Vaccine ; 32(46): 6075-83, 2014 Oct 21.
Article em En | MEDLINE | ID: mdl-25239481
Risk groups with increased vulnerability for influenza complications such as pregnant women, persons with underlying illnesses as well as persons who come into contact with them, such as health care workers, are currently given priority (along with other classic target groups) to receive seasonal influenza vaccination in Belgium. We aimed to evaluate this policy from a health care payer perspective by cost-effectiveness analysis in the three specific target groups above, while accounting for effects beyond the target group. Increasing the coverage of influenza vaccination is likely to be cost-effective for pregnant women (median €6589 per quality-adjusted life-year (QALY) gained [€4073-€10,249]) and health care workers (median €24,096/QALY gained [€16,442-€36,342]), if this can be achieved without incurring additional administration costs. Assuming an additional physician's consult is charged to administer each additional vaccine dose, the cost-effectiveness of vaccinating pregnant women depends strongly on the extent of its impact on the neonate's health. For health care workers, the assumed number of preventable secondary infections has a strong influence on the cost-effectiveness. Vaccinating people with underlying illnesses is likely highly cost-effective above 50 years of age and borderline cost-effective for younger persons, depending on relative life expectancy and vaccine efficacy in this risk group compared to the general population. The case-fatality ratios of the target group, of the secondary affected groups and vaccine efficacy are key sources of uncertainty.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 5_ODS3_mortalidade_materna Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Vacinação / Análise Custo-Benefício / Pessoal de Saúde / Influenza Humana Tipo de estudo: Evaluation_studies / Health_economic_evaluation Aspecto: Patient_preference Limite: Female / Humans / Pregnancy País/Região como assunto: Europa Idioma: En Revista: Vaccine Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 5_ODS3_mortalidade_materna Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Vacinação / Análise Custo-Benefício / Pessoal de Saúde / Influenza Humana Tipo de estudo: Evaluation_studies / Health_economic_evaluation Aspecto: Patient_preference Limite: Female / Humans / Pregnancy País/Região como assunto: Europa Idioma: En Revista: Vaccine Ano de publicação: 2014 Tipo de documento: Article